A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantation (R3ACT Randomised (R3R)) (ACTRN12620000171910p)
R3ACT-R
This trial is Currently recruiting
Registration number ACTRN12620000171910p
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principle investigator
Dr Shu Wong
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.